About Bioline  All Journals  Testimonials  Membership  News  Donations

African Journal of Biomedical Research
Ibadan Biomedical Communications Group
ISSN: 1119-5096
Vol. 17, No. 2, 2014, pp. 129-133
Bioline Code: md14019
Full paper language: English
Document type: Short Communication
Document available free of charge

African Journal of Biomedical Research, Vol. 17, No. 2, 2014, pp. 129-133

 en Prevalence of methicillin resistant Staphylococcus aureus check for this species in other resources and resistance pattern of its clinical strains to beta-lactam antibiotics
Ayeni, F.A.; Olatunji, D.F. & Ogunniran, M.


Staphylococcus aureus check for this species in other resources is the leading overall cause otf nosocomial infections with increasing resistance to β lactam antibiotics. This study was carried out to study the current resistant/susceptibility pattern of S. aureus to β lactam antibiotics and prevalence of Methicillin Resistant S. aureus (MRSA) in the studied population. Clinical isolates of S. aureus strains were collected from Medical Microbiology Unit of University College Hospital, Ibadan between May and October, 2012. The isolates were confirmed through growth on Mannitol Salt Agar (MSA) and tube coagulase test. The susceptibility / resistance pattern of the S. aureus strains to antibiotics were tested by disc diffusion method. Fifty studied S. aureus strains were highly resistant to Amoxycillin (92%), Aztreonam (70%), but high susceptibility was observed to Imipenem (90%), Cefotaxime (62%), Ceftazidine (50%), Cefoxitin (66%), Ceftriazone (52%), Amoxycillin/Clavulanic acid (50%), S. aureus strains (42%) that were resistant to amoxicillin were susceptible to amoxicillin/clavulanic acid while 34% of the studied S. aureus strains were MRSA. The relatively high prevalence of MRSA in the studied S. aureus strains call for surveillance studies and implementation policies in control of MRSA. Cephalosporins are still relatively effective for treatment of S. aureus infections. The observed synergy in this study between imipenem and aztreonam is an indication that combine therapy of imipenem and aztreonam will lead to enhanced antimicrobial activity of aztreonam.

Antibiotics; Resistance; S. aureus; MRSA

© Copyright 2014 - African Journal of Biomedical Research

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2019, Site last up-dated on 02-May-2019.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil